Management of hepatic sarcoidosis
Background and Aims: Liver involvement in sarcoidosis may occur in up to 60% of all patients. As many patients experience only minor symptoms, a high number of undiagnosed cases must be assumed. In order to successfully identify patients with hepatic sarcoidosis, a throughout characterization of the...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
15 Sep. 2022
|
| In: |
Journal of gastrointestinal and liver diseases
Year: 2022, Jahrgang: 31, Heft: 3, Pages: 323-330 |
| ISSN: | 1842-1121 |
| DOI: | 10.15403/jgld-4122 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.15403/jgld-4122 Verlag, lizenzpflichtig, Volltext: https://www.jgld.ro/jgld/index.php/jgld/article/view/4122 
|
| Verfasserangaben: | Janina Sollors, Bernhard Schlevogt, Hartmut J. Schmidt, Marcus Wörns, Peter R. Galle, Yuquan Qian, Christoph Antoni, Cleo-Aron Weis, Svetlana Hetjens, Raoul Bergner, Matthias P. Ebert, Andreas Teufel |
| Zusammenfassung: | Background and Aims: Liver involvement in sarcoidosis may occur in up to 60% of all patients. As many patients experience only minor symptoms, a high number of undiagnosed cases must be assumed. In order to successfully identify patients with hepatic sarcoidosis, a throughout characterization of these patients and their course of disease is necessary. - Methods: We collected 40 patients from four German centers to evaluate current treatment standards and course of disease. All of our patients underwent liver biopsy with histologically proven granulomatous hepatitis. - Results: Detailed characterization of our patients showed an overall benign course of disease. Treatment was very diverse with glucocorticoids for 1 year in 55% (22/40), 5-10 years in 18% (7/40), and permanently in 18% (7/40). Other treatments included disease-modifying anti-rheumatic drugs (DMARDs), the conventional non-biological type in 53% of all patients (of these 81% received azathioprine, 46% metotrexate, 10% hydroxychloroquine, 10% mycophenolate mofetil and 10% cyclophosphamide and biologicals in 8%. Despite these very diverse treatments, patients generally showed slow progression of the disease. Two patients died. None of our patients received a liver transplantation. - Conclusions: Patients received diverse treatments and generally showed slow progression of the disease. Based on our experience, we proposed a diagnostic work up and surveillance strategy as a basis for future, prospective register studies. |
|---|---|
| Beschreibung: | Gesehen am 18.01.2023 |
| Beschreibung: | Online Resource |
| ISSN: | 1842-1121 |
| DOI: | 10.15403/jgld-4122 |